PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS

Pfizer (PFE) announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its oncology drug, Braftovi (encorafenib), for treating patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation. Braftovi is an oral small-molecule kinase inhibitor that targets BRAF V600E.The phase III BREAKWATER study is evaluating the candidate's safety and efficacy in combination with Eli Lilly’s (LLY) Erbitux (cetuximab) and chemotherapy (mFOLFOX6) in mCR ...